Plasma Neurofilament Light (NfL) in Patients Affected by Niemann–Pick Type C Disease (NPCD)
Authors:
- Andrea DardisAndrea Dardis
- Eleonora PavanEPEleonora Pavan
- Martina FabrisMFMartina Fabris
- Rosalia Maria Da RiolRRRosalia Maria Da Riol
- Annalisa SechiASAnnalisa Sechi
- Agata FiumaraAFAgata Fiumara
- Lucia SantoroLSLucia Santoro
- Maximiliano OrmazabalMOMaximiliano Ormazabal
- Romina MilanicRMRomina Milanic
- Stefania ZampieriSZStefania Zampieri
- Jessica BiasizzoJBJessica Biasizzo
- Maurizio ScarpaMSMaurizio Scarpa
Open Access
- 19 October 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (20) , 4796
Abstract
(1) Background: Niemann–Pick type C disease (NPCD) is an autosomal recessive lysosomal storage disorder caused by mutations in the NPC1 or NPC2 genes. The clinical presentation is characterized by visceral and neurological involvement. Apart from a small group of patients presenting a severe perinatal form, all patients develop progressive and fatal neurological disease with an extremely variable age of onset. Different biomarkers have been identified; however, they poorly correlate with neurological disease. In this study we assessed the possible role of plasma NfL as a neurological disease-associated biomarker in NPCD. (2) Methods: Plasma NfL levels were measured in 75 healthy controls and 26 patients affected by NPCD (24 NPC1 and 2 NPC2; 39 samples). (3) Results: Plasma NfL levels in healthy controls correlated with age and were significantly lower in pediatric patients as compared to adult subjects (p = 0.0017). In both pediatric and adult NPCD patients, the plasma levels of NfL were significantly higher than in age-matched controls (p < 0.0001). Most importantly, plasma NfL levels in NPCD patients with neurological involvement were significantly higher than the levels found in patients free of neurological signs at the time of sampling, both in the pediatric and the adult group (p = 0.0076; p = 0.0032, respectively). Furthermore, in adults the NfL levels in non-neurological patients were comparable with those found in age-matched controls. No correlations between plasma NfL levels and NPCD patient age at sampling or plasma levels of cholestan 3β-5α-6β-triol were found. (4) Conclusions: These data suggest a promising role of plasma NfL as a possible neurological disease-associated biomarker in NPCD.Keywords
This publication has 50 references indexed in Scilit:
- Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological DiseasesPLOS ONE, 2013
- Niemann-Pick disease type C symptomatology: an expert-based clinical descriptionOrphanet Journal of Rare Diseases, 2013
- Recommendations for the diagnosis and management of Niemann–Pick disease type C: An updateMolecular Genetics and Metabolism, 2012
- A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasmaJournal of Lipid Research, 2011
- Cholesterol Oxidation Products Are Sensitive and Specific Blood-Based Biomarkers for Niemann-Pick C1 DiseaseScience Translational Medicine, 2010
- Niemann-Pick disease type COrphanet Journal of Rare Diseases, 2010
- Genetic and clinical peculiarities in a new family with hereditary hypophosphatemic rickets with hypercalciuria: a case reportOrphanet Journal of Rare Diseases, 2010
- Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and lossJournal of the Neurological Sciences, 2005
- Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up studyJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Neuronal Intermediate FilamentsAnnual Review of Neuroscience, 1996